Peptides corresponding to the predicted heptad repeat 2 domain of the feline coronavirus spike protein are potent inhibitors of viral infection.
Peptides corresponding to the predicted heptad repeat 2 domain of the feline coronavirus spike protein are potent inhibitors of viral infection.
复制标题
DOI:
10.1371/journal.pone.0082081
复制
发表时间:
2013
期刊:
影响因子:
3.7
通讯作者:
Chueh LL
中科院分区:
文献类型:
--
作者:
Liu IJ;Tsai WT;Hsieh LE;Chueh LL
Feline infectious peritonitis (FIP) is a lethal immune-mediated disease caused by feline coronavirus (FCoV). Currently, no therapy with proven efficacy is available. In searching for agents that may prove clinically effective against FCoV infection, five analogous overlapping peptides were designed and synthesized based on the putative heptad repeat 2 (HR2) sequence of the spike protein of FCoV, and the antiviral efficacy was evaluated. Plaque reduction assay and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cytotoxicity assay were performed in this study. Peptides were selected using a plaque reduction assay to inhibit Feline coronavirus infection. The results demonstrated that peptide (FP5) at concentrations below 20 μM inhibited viral replication by up to 97%. The peptide (FP5) exhibiting the most effective antiviral effect was further combined with a known anti-viral agent, human interferon-α (IFN-α), and a significant synergistic antiviral effect was observed. Our data suggest that the synthetic peptide FP5 could serve as a valuable addition to the current FIP prevention methods.
登录
查看更多内容
影响因子:
3.8
作者:
Pan, Chungen;Lu, Hong;Jiang, Shibo
通讯作者:
Jiang, Shibo
DOI:
10.1074/jbc.m110.207084
发表时间:
2011-05-06
期刊:
The Journal of biological chemistry
影响因子:
--
作者:
Miller EH;Harrison JS;Radoshitzky SR;Higgins CD;Chi X;Dong L;Kuhn JH;Bavari S;Lai JR;Chandran K
通讯作者:
Chandran K
影响因子:
3.7
作者:
Ballesteros, ML;Sanchez, CM;Enjuanes, L
通讯作者:
Enjuanes, L
DOI:
10.1016/s0190-9622(03)02099-1
发表时间:
2003-11-01
影响因子:
13.8
作者:
Ball, RA;Kinchelow, T
通讯作者:
Kinchelow, T
影响因子:
7.6
作者:
Liu IJ;Kao CL;Hsieh SC;Wey MT;Kan LS;Wang WK
通讯作者:
Wang WK